markets

8/25/25

Warren Buffett says he’s not looking to buy a second railroad, sending CSX shares down

One massive railroad is enough for Warren Buffett, for the time being.

The Berkshire Hathaway chairman told CNBC that his railroad, BNSF, would not acquire rival CSX. CSX shares fell more than 5% on the news.

Rumors swirled around the potential for a Berkshire-led railroad megamerger following the proposed $85 billion combination of Union Pacific and Norfolk Southern last month. That deal, if approved, would create America’s first coast-to-coast freight rail network and establish a company with more than 50,000 employees.

Buffett told CNBC that he met with CSX’s CEO earlier this month to discuss deeper cooperation. Last week, the companies announced a plan to provide coast-to-coast rail services.

Warren Buffett just told CNBC his plan for trains. The stocks are moving

Warren Buffett just told CNBC his plan for trains. The stocks are moving

Rumors swirled around the potential for a Berkshire-led railroad megamerger following the proposed $85 billion combination of Union Pacific and Norfolk Southern last month. That deal, if approved, would create America’s first coast-to-coast freight rail network and establish a company with more than 50,000 employees.

Buffett told CNBC that he met with CSX’s CEO earlier this month to discuss deeper cooperation. Last week, the companies announced a plan to provide coast-to-coast rail services.

More Markets

See all Markets

Robinhood, Amcor, Applovin surge on after being added to S&P 500

Robinhood, AppLovin vault higher as the "inclusion effect" is in full force

Membership has its privileges.

Matt Phillips2h

markets

J. Edward Moreno

2h

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

Gold is outperforming the Nasdaq 100 since the launch of ChatGPT

There’s a bull market in anti-humanity.

Close-up of gold bars

markets

J. Edward Moreno

3h

UNH rises after saying it plans to reiterate outlook

UnitedHealth rose 2% in early trading after it disclosed that it plans to reiterate its full-year earnings outlook when it meets with investors this week.

The company said on July 29 that it was expects to report annual adjusted earnings per share of at least $16. The company had previously pulled full-year guidance and prior to that withdrawal, had told investors it expected to see earnings of $26 to $26.50 per share.

Currently, a analysts polled by FactSet are penciling in $16.23, compared to $17.21 before the guidance came down.

UnitedHealth has had a tumultuous year as he industry has been hit with rising costs of care, and UnitedHealth specifically has been hit with investigations into its Medicare Advantage practices. It recently got a boost after Warren Buffett's Berkshire Hathaway revealed that it's built a stake in the company

markets

4h

T-Mobile and other wireless carriers tumble on SpaceX’s purchase of spectrum licenses from EchoStar

T-Mobile is the worst-performing S&P 500 constituent in early trading, off 5.2% as of 8:27 a.m. ET.

The reason why? SpaceX purchased a pair of spectrum licenses from EchoStar for roughly $17 billion, and as such, SpaceX might no longer need to rely as heavily on T-Mobile going forward.

In August 2022, T-Mobile and SpaceX announced a partnership in which the carrier would help SpaceX’s Starlink provide mobile connectivity from space. The first such satellites launched in January 2024, and T-Mobile ran an ad during the 2025 Super Bowl touting a beta trial of Starlink-powered satellite texting.

However, other wireless providers like AT&T and Verizon are also down (4.5% and 4.2%, respectively) ahead of the open, so this may also simply be a selloff linked to the wireless providers not being the ones to purchase these valuable spectrum licenses themselves — even though AT&T struck a deal with EchoStar in late August to purchase $23-billion in spectrum assets.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2025 Sherwood Media, LLC